New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:51 EDTIPG, APRI, MHFI, NYCBHigh option volume stocks: IPG VXZ APRI MHFI NYCB
News For IPG;APRI;MHFI;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
10:08 EDTMHFIMcGraw Hill Financial says Italian judge issues indictments against S&P
In a filing, McGraw Hill Financial notes that on January 15, S&P Ratings received notification of a potential claim by the Prosecutor General of the Corte dei Conti, an Italian administrative court, with respect to whether S&P Ratings’ downgrade of Italian sovereign debt in May 2011 wrongfully damaged Italy’s public finances and international reputation and whether S&P Ratings should pay compensation to Italy for the costs of Italian budget adjustments and for ancillary damages in an amount “not lower than” EUR234B. The prosecutor in the Italian city of Trani is seeking criminal indictments against several current and former S&P Ratings managers and ratings analysts for alleged market manipulation, and against Standard & Poor’s Credit Market Services Europe under Italy’s vicarious liability statute, for having allegedly failed to properly supervise the ratings analysts and prevent them from committing market manipulation. The prosecutor’s theories are based on various actions by S&P Ratings taken with respect to Italian sovereign debt between May 2011 and January 2012. On October 28, 2014, the court granted the prosecutor’s request and issued indictments against the current and former S&P Ratings managers and ratings analysts, as well as Standard & Poor's Credit Market Services Europe.
07:12 EDTMHFIMcGraw Hill Financial incurred $46M of pre-tax restructuring charges in Q3
Subscribe for More Information
07:12 EDTMHFIMcGraw Hill Financial cuts FY14 EPS to $3.78-$3.83 from $3.80-$3.90
FY14 EPS consensus of $3.86. With the recently announced agreement to sell the McGraw Hill Construction business, its year-to-date results, including directly attributable shared costs, have now been reclassified to discontinued operations. The Company is modestly adjusting its guidance as a result of the sale.
07:11 EDTMHFIMcGraw Hill Financial reports Q3 adjusted EPS $1.02, consensus 94c
Subscribe for More Information
October 28, 2014
15:44 EDTMHFINotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Southern Company (SO), consensus $1.07; Phillips 66 (PSX), consensus $1.75; Automatic Data Processing (ADP), consensus 60c; Praxair (PX), consensus $1.63; WellPoint (WLP), consensus $2.27; Exelon (EXC), consensus 73c; Eaton (ETN), consensus $1.23; Hess (HES), consensus $1.08; TE Connectivity (TEL), consensus $1.00; McGraw Hill Financial (MHFI), consensus 94c; Waste Management (WM), consensus 68c; Hershey (HSY), consensus $1.08; Ralph Lauren (RL), consensus $2.06; Wisconsin Energy (WEC), consensus 53c; Garmin (GRMN), consensus 71c; Sealed Air (SEE), consensus 46c; DENTSPLY (XRAY), consensus 60c; Goodyear Tire (GT), consensus 70c; Revlon (REV), one estimate 45c; Booz Allen (BAH), consensus 41c; Carlyle Group (CG), consensus 54c.
12:43 EDTAPRIApricus Biosciences downgraded to Hold from Buy at Cantor
Cantor Fitzgerald downgraded Apricus Biosciences to Hold and lowered its price target for shares to $1.50 from $3 citing the dilutive equity sale to Aspire Capital.
October 23, 2014
12:27 EDTIPGInterpublic Group management to meet with Jefferies
Subscribe for More Information
October 22, 2014
07:13 EDTNYCBNew York Community Bancorp reports Q3 loans originated for investment $2.6B
Reports Q3 non-performing non covered assets fell $30.2M or 17.2% from last year. Reports margin rose three basis points quarter-over-quarter to 2.69% in Q3. Reports Q3 non-covered loans held for investment represented $32.3B, or 91.0%, of total loans at the end of September.
07:05 EDTIPGInterpublic Group reports Q3 EPS 21c, consensus 21c
Subscribe for More Information
07:03 EDTNYCBNew York Community Bancorp reports Q3 cash EPS 29c, consensus 26c
Subscribe for More Information
October 21, 2014
15:35 EDTIPGNotable companies reporting before tomorrow's open
Subscribe for More Information
October 20, 2014
06:13 EDTAPRIApricus Biosciences to host conference call
Subscribe for More Information
05:27 EDTAPRIApricus licensed U.S. development, commercialization rights for fispemifene
Apricus Biosciences announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, or SERM, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. This license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men. Under the terms of the agreement, Forendo and its advisors received an upfront license fee of $12.5M comprised of a $5M cash payment and the issuance of $7.5M in Apricus common stock; approximately 3.6M shares priced at the 360-day average market price of $2.08 per share. The agreement includes additional potential clinical and regulatory milestone payments to Forendo of up to $45M, including for potential FDA approval, as well as potential commercial milestone payments totaling up to $260M, based on achieving specified annual net sales levels up to $1B in the U.S. Apricus will also pay tiered low double-digit royalties based on net sales once the product is commercialized. Apricus will be responsible for the clinical development of fispemifene in the U.S., as well as all future commercialization efforts in the U.S. and its territories.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use